Monoclonal antibody therapeutics: Leading companies to maximise sales and market share

被引：9

作者：

机构：

来源：

J. Commer. Biotechnol. | 2008年 / 1卷 / 65-72期

关键词：

Monoclonal antibodies;

D O I：

10.1057/palgrave.jcb.3050081

中图分类号：

学科分类号：

摘要：

A close look at the biology and pharmacology of monoclonal antibodies reveals both their continuing promise as therapeutic agents to address unmet medical needs, as well as a number of challenges to the future discovery and development of this unique class of biologics. A remarkably consistent experience of reliable clinical efficacy and safety ensures that Biotech and Pharma have strong incentives to accelerate the antibody drug discovery process. Their attractive commercial potential invites consideration of potential challenges to the future expansion of the monoclonal antibody drug market. Four challenges arise from scientific and technical aspects of the antibody drug format: drug target limitations, biodistribution limitations, species specificity issues, and limitations to the route of administration and four challenges are based in the commercial and clinical use of antibody drugs: cost of goods, product differentiation within the antibody market, competition from small molecule drugs, and price sensitivity of clinical acceptance. Despite these challenges and recent setbacks, such as the withdrawal and subsequent relaunch of Tysabri and the TGN1412 Phase I disaster, the prevailing opinion is that monoclonal antibodies will continue to be safe and effective medicines that are worthy of commercialisation.

引用

页码：65 / 72

页数：7

共 10 条

[1]

Fuh G., Synthetic antibodies as therapeutics, Expert. Opin. Biol. Ther, 7, 1, pp. 73-87, (2007)

[2]

Garcia-Rodriguez C., Levy R., Arndt J.W., Forsyth C.M., Razai A., Lou J., Geren I., Stevens R.C., Marks J.D., Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin, Nat. Biotechnol, 25, 1, pp. 107-116, (2007)

[3]

Baker M., Upping the ante on antibodies, Nat. Biotechnol, 23, 9, pp. 1065-1072, (2005)

[4]

Wiles M., Andreassen P., Monoclonals - The billion dollar molecules of the future, Drug. Disc. World, 7, 4, pp. 17-23, (2006)

[5]

Jarvis L.M., Biotechs rely on old products, Chem. Eng. News, 85, 34, pp. 34-35, (2007)

[6]

Carter P.J., Potent antibody therapeutics by design, Nat. Rev. Immunol, 6, 5, pp. 343-357, (2006)

[7]

Stebbings R., Findlay L., Edwards C., Eastwood D., Bird C., North D., Mistry Y., Dilger P., Liefooghe E., Cludts I., Fox B., Tarrant G., Robinson J., Meager T., Dolman C., Thorpe S.J., Bristow A., Wadhwa M., Thorpe R., Poole S., Cytokine Storm in the phase I trial of monoclonal antibody TGN1412: Better understanding the causes to improve preclinical testing of immunotherapeutics, J. Immunol, 179, 5, pp. 3325-3331, (2007)

[8]

Schwartzman S., Morgan G.J., Does route of administration affect the outcome of TNF antagonist therapy, Arthritis. Res. Ther, 6, SUPPL. 2, (2004)

[9]

Schrag D., The price tag on progress - Chemotherapy for colorectal cancer, N. Engl. J. Med, 351, 4, pp. 317-319, (2004)

[10]

Hawkes N., Patients angered as watchdog refuses to allow bowel cancer drugs on NHS, The Times, (2006)

← 1 →